Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Long-Term Capital Lease Obligation : HK$161 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Long-Term Capital Lease Obligation?

Biocytogen Pharmaceuticals (Beijing) Co's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$161 Mil.

Biocytogen Pharmaceuticals (Beijing) Co's quarterly Long-Term Capital Lease Obligation declined from Dec. 2023 (HK$183 Mil) to Jun. 2024 (HK$169 Mil) and declined from Jun. 2024 (HK$169 Mil) to Dec. 2024 (HK$161 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual Long-Term Capital Lease Obligation declined from Dec. 2022 (HK$214 Mil) to Dec. 2023 (HK$183 Mil) and declined from Dec. 2023 (HK$183 Mil) to Dec. 2024 (HK$161 Mil).

Biocytogen Pharmaceuticals (Beijing) Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Long-Term Capital Lease Obligation Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

79.20

77.02

213.86

182.67

160.63

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial				213.86	204.29	182.67	168.69	160.63

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Biocytogen Pharmaceuticals (Beijing) Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

I54:Germany

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Executives

Shen Yuelei
Ni Jian
Zhao Shang Yin Xing Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Cmbi Private Equity Series Spc	2201 Interest of corporation controlled by you
Cmb International Private Investment Limited	2201 Interest of corporation controlled by you
Cmb International Investment Management Limited	2201 Interest of corporation controlled by you
Astral Eminent Limited	2101 Beneficial owner
Wei Ke Xiang Gang Jing Mao You Xian Gong Si	2101 Beneficial owner
Bioveda China Fund Ii Rmb, Limited	2101 Beneficial owner
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd.	2201 Interest of corporation controlled by you
Yang Zhi	2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines